RAPP vs ACAD

ACADIA Pharmaceuticals Inc.

(ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Rapport Therapeutics, Inc. Common Stock (RAPP) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Rapport Therapeutics, Inc.

Common Stock (RAPP) delivered a total return of +92. 0%, compared to +7. 1% for ACADIA Pharmaceuticals Inc. (ACAD). Over 10 years, the gap is even starker: RAPP returned +92. 0% versus ACAD's -22. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), ACADIA Pharmaceuticals Inc.

(ACAD) is the lower-risk stock at 1. 26β versus Rapport Therapeutics, Inc. Common Stock's 1. 55β — meaning RAPP is approximately 23% more volatile than ACAD relative to the S&P 500. On balance sheet safety, Rapport Therapeutics, Inc. Common Stock (RAPP) carries a lower debt/equity ratio of 2% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc.

grew EPS 68. 4% year-over-year, compared to 24. 3% for Rapport Therapeutics, Inc. Common Stock. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -536. 4% for Rapport Therapeutics, Inc. Common Stock — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -611. 0% for RAPP. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ACAD: 54.

1% to $34. 78.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Rapport Therapeutics, Inc. Common Stock (RAPP) carries a higher beta of 1. 55 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ACAD: -22. 9%, RAPP: +92. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RAPP is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.